Evaluation of the androgen receptor in patients with ERα-positive early breast cancer treated with adjuvant tamoxifen ± fluoxymesterone
Our findings suggest that an AR-agonist may be of value in AR-enriched, ER-enriched breast cancers and should be studied in future trials because of the availability of new, more tolerable AR-agonists.
Authors
- Matthew P. Goetz (ORCID: https://orcid.org/0000-0002-4383-270X)
- Marie R. Passow (ORCID: https://orcid.org/0000-0002-9957-8878)
- Jordan D. Campbell
- Vera J. Suman (ORCID: https://orcid.org/0000-0002-9640-5189)
- James N. Ingle (ORCID: https://orcid.org/0000-0003-1257-7731)
- Liewei Wang
- Malvika Solanki (ORCID: https://orcid.org/0000-0001-6211-1599)
Institutions
- Mayo Clinic (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- Breast Cancer Research
- Published
- 2025-03-19
- DOI
- https://doi.org/10.1186/s13058-025-01992-0
- Primary Topic
- Estrogen and related hormone effects
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Breast Cancer Research Foundation
- George M. Eisenberg Foundation for Charities
- Max-Planck-Gesellschaft
- National Institutes of Health